Review papers by their claims

Figure A — Nanowell depth before vs after hybridization (AFM)

Data source: AFM depth profile reported by the authors (depth reduced from ≈200 nm to ≈15 nm after streptavidin/SAM + probe/target hybridization) — interpreted as strong local occupancy of wells by hybrid complex but not proof of single-molecule capture per well. Cha et al. AFM data

Figure B — Claimed analytical dynamic range and LOD (schematic)

Authors report quantitative detection over concentration range 1 pM — 1 µM and state the limit of detection (LOD) is 1 pM on their device (EIS using Rct). The plot above is a schematic (raw Rct numerical values and errors were not provided in the text), used here to visualize the claimed dynamic range and LOD. Cha et al. EIS calibration claim

Figure C — Evidence chain and main blindspots (visual)

• Well-supported steps: fabrication and SEM/AFM characterization; SAM chemistry and streptavidin/biotin immobilization; EIS method and high-frequency semicircle attribution to Rct per standard electrochemistry practice.
• Major blindspots / missing data: no tabulated Rct numbers, no replicate statistics or limits of blank/false-positive rates; only synthetic targets in PBS (no serum/clinical matrix); limited batch-to-batch reproducibility data; specificity tested only with single non-complementary 18-mer; no assessment of secondary structure or mismatch discrimination; no demonstration of long-term stability or device-to-device variability.

Citations: methodological details and claims taken from Cha et al. 2013. For context on nanowell sensitivity benefits, compare earlier ONW nanowell work (2006) that demonstrates nanoscale confinement can boost electrochemical sensitivity but also highlights scalability and real-sample challenges. Cha et al. methods and claims ONW 2006 sensitivity and limitations

Concise critical synthesis (evidence-weighted)

1. What the paper shows (supported): robust nanofabrication and surface chemistry workflow, AFM evidence of nanowell occupation after immobilization/hybridization, EIS Nyquist semicircle growth consistent with increased Rct on hybridization (Cha et al. Nyquist/EIS).
2. What is not proven / overclaimed: analytical performance in realistic biological matrices (serum, nasal swabs) and sensor robustness across devices; raw Rct data and uncertainty estimates (SD, n) are missing; only one non-complementary control tested — limited cross-reactivity analysis; dynamic range claim (1 pM–1 µM) lacks tabulated data and statistical treatment in text.
3. Reproducibility risk factors: SAM and streptavidin layers are notoriously variable; immobilized probe density not quantified; hybridization time 15 min may be insufficient for low-concentration samples in complex fluids; device fabrication yield and inter-chip variability not reported (57 chips produced but no per-chip performance distribution published).
4. Next critical experiment(s) needed: (a) provide tabulated Rct vs concentration with replicate N and SD; (b) test limit-of-blank and limit-of-detection per CLSI guidance using multiple blanks and low-conc replicates; (c) spike-and-recovery in serum and swab matrix with extraction/denaturation steps; (d) device-to-device reproducibility across wafer batches and storage stability.

Bottom-line (evidence-weighted)

The paper provides a credible nanofabrication + surface-chemistry demonstration and orthogonal AFM + EIS signals that are consistent with probe-target hybridization. However, the analytical claims (LOD = 1 pM and wide dynamic range) are insufficiently supported in the text because numeric Rct values, replicate statistics, blank controls, and matrix-challenge data are missing; therefore the assertion that the device is ready for biological H5N1 detection (clinical specimens) is premature. Confidence in the core fabrication and measurement approach is moderate; confidence in the analytical performance claims in real samples is low without follow-up experiments. Cha et al. claims and limitations

Author reviews